Moderate

Chronic thromboembolic pulmonary hypertension (CTEPH)

Group 4 pulmonary hypertension · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

CTEPH is pulmonary hypertension from organised thromboembolic obstruction of the pulmonary arteries, often following acute PE. It is the only potentially curable form of pulmonary hypertension, via pulmonary endarterectomy, and must be actively sought after unresolved PE symptoms.

Red flags

  • Progressive right heart failure
  • Syncope on exertion
  • Haemoptysis
  • Rapidly rising pulmonary pressures
  • Persistent breathlessness after 'treated' PE

Assessment

Differential diagnosis

  • Idiopathic pulmonary arterial hypertension
  • Recurrent acute pulmonary embolism
  • Pulmonary vasculitis / arteritis
  • Fibrosing mediastinitis
  • Pulmonary artery sarcoma
  • Left-heart disease-related PH

Investigations

  • Ventilation/perfusion (V/Q) scan (screening test of choice)
  • CT pulmonary angiography for chronic clot morphology
  • Right-heart catheterisation to confirm precapillary PH
  • Echocardiogram for RV function and PA pressure estimate
  • Pulmonary angiography for operability assessment
  • Thrombophilia and antiphospholipid screen

Management

  • Suspect CTEPH in persistent breathlessness months after acute PE
  • Screen with a V/Q scan — a normal scan effectively excludes CTEPH
  • Confirm precapillary pulmonary hypertension on right-heart catheterisation
  • Ensure at least 3 months of therapeutic anticoagulation before operability assessment
  • Refer every confirmed case to an expert CTEPH/pulmonary endarterectomy centre
  • Assess operability with multidisciplinary review and pulmonary angiography
  • Offer pulmonary endarterectomy as the treatment of choice for operable disease
  • Offer balloon pulmonary angioplasty for inoperable or residual disease
  • Start riociguat for inoperable or persistent/recurrent PH after surgery
  • Continue lifelong anticoagulation
  • Manage right heart failure with diuretics and oxygen as needed
  • Arrange specialist long-term follow-up

Drugs & doses

Lifelong anticoagulation — apixaban 5 mg PO BD or warfarin (target INR 2-3)
Riociguat 1 mg PO TDS titrated to 2.5 mg TDS (soluble guanylate cyclase stimulator)
Furosemide 20-80 mg PO/IV for right heart failure congestion
Consider additional PAH-targeted therapy in specialist centres

Disposition

Refer to a specialist CTEPH/pulmonary endarterectomy centre for operability assessment. Lifelong anticoagulation and PH follow-up.

Complications & pitfalls

  • Progressive right ventricular failure
  • Sudden cardiac death
  • Perioperative mortality with endarterectomy
  • Residual pulmonary hypertension after surgery
  • Haemoptysis

Exam pearls

  • A V/Q scan, not CTPA, is the screening test of choice for CTEPH
  • Pulmonary endarterectomy can be curative — always assess operability
  • Every suspected case belongs at an expert centre
  • Never combine riociguat with a PDE5 inhibitor (profound hypotension)
  • Up to a few percent of acute PE survivors develop CTEPH — follow up persistent symptoms

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.